Gulu University Seeks Shs3.7 Billion to Produce New Covid-19 Drug


By Robert Edwomu



As Uganda joins the world in finding remedy for the Covid-19 pandemic ravaging mankind, Authorities of Gulu University have revealed that they need 3.7 billion shillings to finalize the Covilyce-1 concoction processes for mass production.

James Onono Okot, the Public Relations Officer Gulu University says despite the fact that National Drug Authority (NDA) processes have to be followed, the University is financially constrained to have all these met to enable the product to hit the market.

Recently, Gulu University delivered good news of hope about the discovery of a Covid-19 Herb that allegedly cures corona virus in 72 hours.

The herb dubbed ‘’Covilyce’’ is alleged to have worked wonders on over 100 patients that tried it.

Dr Alice Veronica Lamwaka, the principal of the Pharmaceutical Biotechnology and Traditional Medicine Centre of Excellence at Gulu University is the brain behind the Covilyce herb.

Dr Lamwaka in earlier interviews with different media houses said the University’s herbal COVID-19 treatment drug will be on the market very soon.

Despite the pressure from the communities calling and visiting the premises demanding for the Medicine, Okot says they have restricted the drug from public the  market until clinical trials and NDA approval is made but the community pressure is mounting daily.

However, due to lack of production line, the pressure has forced the inventor to pound the herbs using mortar and pestle and manually pack for some individuals at a free cost.

He further intimates that the University was not ready to reveal any information about the new development but the recovered patients that used the concoction unleashed the information before approvals.

Gulu University joins Mbarara University, the epitome of Covidex, an indigenous herb that is already approved and on the market for Covid-19 fight.




Robert Edwomu
Field Journalist

Tel. 0786463245/0756317003

Back to top button
Verified by MonsterInsights